Pharmacokinetic and exploratory exposure –response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

ConclusionOverall, the limited available data from this exploratory study suggest that no dose adjustments are needed for pertuzumab when administered in combination with trastuzumab and an EBC chemotherapy regimen.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research